Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $17.26 in the prior trading day, UroGen Pharma Ltd (NASDAQ: URGN) closed at $18.34, up 6.26%. In other words, the price has increased by $6.26 from its previous closing price. On the day, 1.2 million shares were traded. URGN stock price reached its highest trading level at $18.39 during the session, while it also had its lowest trading level at $17.16.
Ratios:
Our goal is to gain a better understanding of URGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 4.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On June 16, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 08 ’25 when Schoenberg Mark sold 871 shares for $19.11 per share. The transaction valued at 16,645 led to the insider holds 149,025 shares of the business.
Smith Jason Drew sold 1,520 shares of URGN for $29,047 on Sep 08 ’25. The General Counsel now owns 43,305 shares after completing the transaction at $19.11 per share. On Sep 08 ’25, another insider, Schoenberg Mark, who serves as the Officer of the company, bought 871 shares for $18.88 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 848484160 and an Enterprise Value of 818999168. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.00. Its current Enterprise Value per Revenue stands at 8.691 whereas that against EBITDA is -6.703.
Stock Price History:
The Beta on a monthly basis for URGN is 1.01, which has changed by 0.44409454 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $21.71, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is -2.71%, while the 200-Day Moving Average is calculated to be 45.41%.
Shares Statistics:
The stock has traded on average 1.25M shares per day over the past 3-months and 1155040 shares per day over the last 10 days, according to various share statistics. A total of 46.20M shares are outstanding, with a floating share count of 40.93M. Insiders hold about 11.53% of the company’s shares, while institutions hold 92.32% stake in the company. Shares short for URGN as of 1757894400 were 7943465 with a Short Ratio of 6.36, compared to 1755216000 on 6869486. Therefore, it implies a Short% of Shares Outstanding of 7943465 and a Short% of Float of 17.44.
Earnings Estimates
The stock of UroGen Pharma Ltd (URGN) is currently being evaluated by 7.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.39, with high estimates of $0.05 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$2.4 and -$3.37 for the fiscal current year, implying an average EPS of -$2.99. EPS for the following year is -$1.33, with 6.0 analysts recommending between -$0.65 and -$2.17.
Revenue Estimates
8 analysts predict $34.71M in revenue for . The current quarter. It ranges from a high estimate of $42.1M to a low estimate of $28.64M. As of . The current estimate, UroGen Pharma Ltd’s year-ago sales were $25.2MFor the next quarter, 8 analysts are estimating revenue of $44.56M. There is a high estimate of $53.34M for the next quarter, whereas the lowest estimate is $32.92M.
A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $136M, while the lowest revenue estimate was $106.03M, resulting in an average revenue estimate of $123.68M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $261.67M in the next fiscal year. The high estimate is $391.48M and the low estimate is $224.5M.
